East Hanover, N.J., June 30, 2022 — Novartis today announced that it has acquired Kedalion Therapeutics and its AcuStream™ technology, an innovative device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye. FLG client, Kedalion Therapeutics, is a clinical-stage,…Read More
Thank you Tim for all your contributions. You helped us navigate a period of rapid growth through an incredibly complex space and we’re grateful for that. We’ve made significant progress under your leadership. You jumped into the deep end and helped us be a better company. I genuinely wish you every success in whatever you choose to do next.